S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

OTCMKTS:NEPH - Nephros Stock Price, Forecast & News

$8.25
+0.19 (+2.36 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$8.11
Now: $8.25
$8.39
50-Day Range
$7.92
MA: $8.54
$10.19
52-Week Range
$3.69
Now: $8.25
$11.35
Volume10,200 shs
Average Volume7,829 shs
Market Capitalization$65.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NEPH
Previous SymbolNASDAQ:NEPH
CUSIPN/A
Phone201-343-5202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.69 million
Book Value$0.89 per share

Profitability

Net Income$-3,400,000.00

Miscellaneous

Employees18
Market Cap$65.69 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.


Nephros (OTCMKTS:NEPH) Frequently Asked Questions

What is Nephros' stock symbol?

Nephros trades on the OTCMKTS under the ticker symbol "NEPH."

How were Nephros' earnings last quarter?

Nephros, Inc. (OTCMKTS:NEPH) announced its earnings results on Wednesday, November, 6th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.00. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.12 million. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%. View Nephros' Earnings History.

What guidance has Nephros issued on next quarter's earnings?

Nephros updated its FY 2019 earnings guidance on Monday, October, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.5-10 million, compared to the consensus revenue estimate of $9.28 million.

What price target have analysts set for NEPH?

3 equities research analysts have issued 1 year target prices for Nephros' shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate Nephros' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 93.9% from the stock's current price. View Analyst Price Targets for Nephros.

What is the consensus analysts' recommendation for Nephros?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nephros.

Has Nephros been receiving favorable news coverage?

Media coverage about NEPH stock has trended positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nephros earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View News Stories for Nephros.

Who are some of Nephros' key competitors?

What other stocks do shareholders of Nephros own?

Who are Nephros' key executives?

Nephros' management team includes the folowing people:
  • Mr. Daron G. Evans, Pres, CEO & Director (Age 45)
  • Mr. Andrew Astor, CFO & COO (Age 62)
  • Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.

Who are Nephros' major shareholders?

Nephros' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.48%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow. View Institutional Ownership Trends for Nephros.

Which major investors are buying Nephros stock?

NEPH stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans and Oliver J Spandow. View Insider Buying and Selling for Nephros.

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nephros' stock price today?

One share of NEPH stock can currently be purchased for approximately $8.25.

How big of a company is Nephros?

Nephros has a market capitalization of $65.69 million and generates $5.69 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Nephros employs 18 workers across the globe.View Additional Information About Nephros.

What is Nephros' official website?

The official website for Nephros is http://www.nephros.com/.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.


MarketBeat Community Rating for Nephros (OTCMKTS NEPH)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  154
MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe NEPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel